Glenmark Presents "Coughayam" - A Unique Yoga Program For Cough In Collaboration With The Yoga Institute

·         The session, in collaboration with The Yoga Institute, is aimed at improving symptoms of cough

·         The session happened online as well as through physical engagements

Glenmark Pharmaceuticals Ltd. (Glenmark), an integrated, research?led, global pharmaceutical company, launches "Coughayam" on the occasion of International Yoga Day, June 21st, '23. This innovative initiative, developed in collaboration with "The Yoga Institute," the world's oldest yoga institute, aims to provide a dedicated yoga program for cough. The event took place from 8:00 am to 9:00 am on June 21st and was conducted through a combination of virtual sessions and physical engagements.

The virtual event allowed participants from across the globe to join the Coughayam program, providing a platform for individuals to learn and practice yoga techniques specifically designed to address cough-related concerns. Additionally, Glenmark's Corporate Social Responsibility (CSR) team actively engaged in physical sessions at five locations – Best School Ahmedabad, YMCA Delhi, GH Raisoni College of Commerce, Science & Technology Nagpur, Ekya School JP Nagar Bangalore & Homi Bhabha Cancer Hospital & & Research Centre Muzaffarpur, Bihar along with 80 locations (West Bengal, Assam, Orissa, Bihar, UP, Punjab, Delhi, Hyderabad, Vijaywada, Kerala, Karnataka, Tamilandu, Maharashtra, Mumbai, Gujarat) of Glenmark’s Majesta division’s field executive HQs. This collaborative effort aims to foster community engagement and promote overall well-being.

Through Coughayam, Glenmark strives to promote holistic health practices and enhance awareness about the benefits of yoga in managing cough-related issues. The event will feature expert instructors from The Yoga Institute, who will guide participants through various yoga asanas, pranayama (breathing exercises), and relaxation techniques, specifically curated to address cough-related discomfort.

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an integrated, research?led, global pharmaceutical company, with a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2021; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2021. The company has also been Great Place To Work® Certified™ in India.  Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), becoming the second Indian Pharmaceuticals company to achieve this approval. The organization has impacted over 2.9 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).